Torrent Pharmaceuticals shares hit a fresh 52-week high of ₹4,681 per share on the NSE, gaining 4.34 percent on Monday following the company's March quarter earnings announcement. According to reports from Moneycontrol, the stock surge came despite the drugmaker reporting a 27 percent decline in consolidated profit after tax for the quarter ended March 31, 2026. The profit after tax stood at ₹364 crore compared with ₹498 crore in the corresponding period of the previous fiscal, primarily due to acquisition-related costs linked to the J.B. Chemicals and Pharmaceuticals deal.
As reported by Moneycontrol, revenue from operations in the fourth quarter rose to ₹4,197 crore from ₹2,959 crore in the year-ago period. The company incurred exceptional items outgo of ₹66 crore during the quarter, as per the regulatory filing. For the full financial year 2025-26, net profit rose to ₹2,138 crore from ₹1,911 crore in the previous fiscal. Revenue for FY26 stood at ₹13,980 crore as against ₹11,516 crore in FY25. The board of the company has recommended a final dividend of ₹9 per equity share of face value ₹5 each.
According to Moneycontrol, revenue from the India business stood at ₹2,215 crore, up 43 percent year-on-year. Revenue from Brazil rose 30 percent to ₹455 crore, while revenue from the US business increased 31 percent to ₹396 crore. The company's India base business grew 15 percent, ahead of the Indian pharmaceutical market growth, while the semaglutide launch gained 38 percent share in the generic market.
As reported by Moneycontrol, Jefferies maintained a 'Buy' rating with a target price of ₹5,350, representing an upside of 19.25 percent from its closing price on Friday at ₹4,486.20 per share. Morgan Stanley maintained an 'Equal Weight' rating with a target price of ₹4,580. The brokerages highlighted that excluding J.B. Pharma, revenue and EBITDA rose 16 percent year-on-year, led by the India business and semaglutide. Torrent expects semaglutide sales of ₹200-250 crore in FY27 and sees it as the company's biggest product launch opportunity so far.
According to Moneycontrol, the J.B. Pharma merger is nearing final approval from the National Company Law Tribunal and cost synergies of ₹400-450 crore remain on track over the next three years. The integration of J.B. Pharma is progressing well with the company remaining on track to achieve first-year cost synergy benefits. Jefferies noted that the March quarter included two months of J.B. Pharma integration and that the results were broadly in line with estimates on a like-to-like basis. The company expects FY27 to be a similar or better year with strong momentum in the India business.
